Related Experiment Video
Updated: Feb 17, 2026
13:19
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
17.2K
Tissue-based biomarkers in prostate cancer.
Timothy N Clinton1, Aditya Bagrodia1, Yair Lotan1
1University of Texas Southwestern Medical Center, Department of Urology, Dallas, Texas.
Expert Review of Precision Medicine and Drug Development
|December 12, 2017
Summary
Novel tissue-based biomarkers enhance prostate cancer prognostication beyond traditional methods. These advancements aid in active surveillance and adjuvant therapy decisions, personalizing patient management.
Area of Science:
- Oncology
- Biomarker Discovery
- Genomics
Background:
- Prostate cancer is a heterogeneous disease with limited predictive accuracy from current risk stratification tools (PSA, Gleason score, tumor stage).
- High-throughput sequencing enables the development of novel tissue-based biomarkers for improved prostate cancer prognostication.
Purpose of the Study:
- To review commercially available tissue-based biomarker assays for prostate cancer management.
- To discuss challenges and future directions in biomarker development and adoption.
Main Methods:
- Review of commercially available tissue-based biomarker assays.
- Discussion of obstacles to biomarker adoption.
- Exploration of investigational biomarker sources.
Main Results:
- Tissue-based biomarkers improve risk stratification for active surveillance and adjuvant therapy decisions.
- Obstacles to widespread adoption include the need for further validation and cost considerations.
- Tumor heterogeneity may limit the prognostic ability of current biomarker techniques.
Conclusions:
- Novel biomarkers offer potential for personalized prostate cancer management.
- Further research and validation are necessary for clinical integration.
- Addressing cost and tumor heterogeneity are crucial for future biomarker development.
